Coronavirus update: recent developments in vaccine research
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
Researchers have developed a new combination of compounds called AB569 which has demonstrated success at fighting deadly pathgoens like Pseudomonas aeruginosa.
A new antibiotic compound has been identified by researchers who designed a machine-learning algorithm to screen millions of molecules.
Researchers have uncovered new antibiotics which prevent bacteria from multiplying, offering a strategy to fight infections.
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A compound that has antimicrobial properties has been found by researchers, which could be used to combat drug-resistant infections.
A novel peptide has been discovered that attacks gram negative bacteria at a previously unknown site of action which presents a promising lead substance for the development of a new antibiotic.
A team of researchers has uncovered the structure of a T-box regulatory mechanism in bacteria, which could aid in the development of novel antibiotics.
A study has revealed an enzyme in bacteria that produces a molecule which is toxic to other bacteria and shows promise as an antibiotic substitute.
A new family of synthetic antibiotics that possess broad anti-Gram-negative antimicrobial activity has been discovered.
Glycans, which are found in mucus, have the ability to regulate how microbes behave and could lead to new therapeutics.
A technique to 'trick' bacteria into revealing pores in their cell walls has been developed and targeting these could make antibiotics more effective.